Johnson & Johnson

Aiming to make lung cancer a disease of the past

More than 80% of people diagnosed with lung cancer will not survive beyond five years a statistic that has remained virtually unchanged for decades.

At Johnson & Johnson, we believe the only way to tackle a challenge with such enormous individual and societal burden as lung cancer is to bring together the unparalleled expertise, science, technology, scale and reach of its Pharmaceutical, Medical Device and Consumer Health sectors to advance innovation in this space.

With patient needs at the center, the Lung Cancer Initiative (LCI) at Johnson & Johnson was created as an R&D engine to develop solutions to prevent, intercept and cure this devastating disease. The LCI brings together the brightest minds and most cutting-edge science from across Johnson & Johnson and works with collaborators worldwide to unleash the full potential of lung cancer science and catalyze new approaches to deliver transformative solutions to help transform the trajectory of lung cancer.

For more information, visit